Good pseudoaccommodation with MICS lens at one year

Article

The new MICS lens (Ioltech-Zeiss) is appropriate for the correction of intermediate vision in pseudophakia, according to Carlos Verges, Jorge Cazal and Marc Menezo of the Department of Ophthalmology, Institut Universitari Dexeus, Barcelona, Spain.

The new MICS lens (Ioltech-Zeiss) is appropriate for the correction of intermediate vision in pseudophakia, according to Carlos Verges, Jorge Cazal and Marc Menezo of the Department of Ophthalmology, Institut Universitari Dexeus, Barcelona, Spain.

The researchers presented the clinical results after one-year experience using the MICS lens. A total of 48 consecutive cataractous patients underwent MICS bimanual surgery and implantation of the lens using an incision of just 1.8 mm. The total diameter of the lens is just 12 mm allowing it to be positioned farther into the posterior plane than usual; 5.5 to 6 mm from the corneal endothelium at the nodal plane. The MTF, in the laboratory, was 92 changing to 80 with tilting conditions of 8º and decentration of 0.5 mm.

The results showed that, at one-year follow-up, 92% of subjects had an uncorrected distance visual acuity (UCDVA) of 20/25 and 96% a best corrected distance visual acuity (BCDVA) >20/25. 65% of patients achieved J3 with distance correction and 98% achieved J5. Two subjects required YAG laser for posterior capsule opacification (PCO) and two showed a folded haptic due to capsular retraction, not affecting vision or lens position. Three subjects reported glistening signs but vision was not affected.

Verges and his co-workers believe that the ability to position the lens at the level of the nodal planes combined with the lens' optical geometry allowing a pseudoaccommodative effect, makes the MICS lens appropriate for correct intermediate vision in pseudophakia.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.